UPDATE: SVB Leerink On Gilead Price Target Cut: Firm Notes Mgmt 'Sees Underlying Demand In HIV Market Recovering Slowly' At +3% Q/Q; Co. Currently Holds 75% Of Treatment Market Share But Firm Sees Revenue & Adj EPS Declining 0.4-0.5% CAGR Through FY25